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SUMMARY STATEMENT: Multiparametric liver MRI was feasible in experimental rat 
models and imaging parameters correlated with gold standard histopathological 
assessments, especially characteristics of fatty liver disease.  
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 ABSTRACT  
Non-invasive quantitation of liver disease using multiparametric MRI could refine 
clinical care pathways, trial design and preclinical drug development. The aim of the 
study was to evaluate the use of multiparametric MRI in experimental models of liver 
disease. Liver injury was induced in rats using 4 or 12 weeks carbon tetrachloride 
(CCl4) intoxication and 4 or 8 weeks methionine and choline deficient (MCD) diet. 
Liver MRI was performed using a 7.0 Tesla small animal scanner at baseline and 
specified timepoints after liver injury.  Multiparametric liver MRI parameters (T1 
mapping, T2* mapping and proton density fat fraction (PDFF)) were correlated with 
gold standard histopathological measures. Mean hepatic T1 increased significantly in 
rats treated with CCl4 for 12 weeks compared to controls (1122±78 ms vs. 959±114 
ms; d=162.7, 95% CI (11.92, 313.4), P=0.038) and correlated strongly with 
histological collagen content (rs=0.717, P=0.037). In MCD diet-treated rats, hepatic 
PDFF correlated strongly with histological fat content (rs=0.819, P<0.0001), steatosis 
grade (rs=0.850, P<0.0001) and steatohepatitis score (rs=0.818, P<0.0001). Although 
there was minimal histological iron, progressive fat accumulation in MCD diet-treated 
liver significantly shortened T2*. In preclinical models, quantitative MRI markers 
correlated with histopathological assessments, especially for fatty liver disease. 
Validation in longitudinal studies is required.  
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 INTRODUCTION 
Chronic liver disease (CLD) caused by obesity, excessive alcohol consumption and 
viral hepatitis represents a significant and increasing healthcare and socio-economic 
burden worldwide. Non-alcoholic fatty liver disease (NAFLD) is now the commonest 
form of CLD with a global prevalence of 25% (Younossi et al., 2016). Despite 
advances in our understanding of the pathogenic mechanisms that underlie NAFLD 
and liver fibrosis in general, there are still no FDA-approved drug therapies. 
Important therapeutic targets and promising drug candidates have been identified in 
preclinical models, but reliable triage of efficacious therapies requires optimization 
and standardization of drug development strategies and consensus on acceptable 
endpoints (Torok et al., 2015). In particular, reproducible and scalable quantitative 
non-invasive markers of chronic liver injury that permit stratification and longitudinal 
monitoring of disease could refine preclinical testing, increase efficiency of trial 
design, and transform clinical care pathways.  
Current clinical trials of potential anti-NASH or antifibrotic drugs are anchored to 
histopathological assessments of disease progression. However, liver biopsy is 
hampered by invasiveness and sampling variability and is unpopular with patients. 
Magnetic resonance imaging (MRI) has emerged as a promising new modality for 
improved understanding and characterization of in vivo liver pathophysiology. It is a 
versatile technique whereby structural and functional MRI can be performed in a 
single multiparametric scan session, depicting changes associated with 
inflammation, fibrosis, steatosis, siderosis, oxygenation, and tissue microstructure. 
Quantitative MRI parameters characterize these processes directly in the liver, 
rather than using downstream/upstream metabolic analytes. Compared to 
histopathology, MRI is non-invasive and avoids sampling bias by characterizing the 
whole organ with high spatial resolution. The MRI proton density fat fraction (PDFF) 
is a highly accurate and reproducible technique for the assessment of steatosis and 
can detect changes in hepatic fat as small as 1% (Noureddin et al., 2013). Magnetic 
resonance elastography (MRE) is a phase-contrast MR technique that measures 
liver stiffness as a surrogate of fibrosis. MRE has high accuracy for the diagnosis of 
advanced liver fibrosis and cirrhosis, but it is not yet known whether it is sufficiently 
sensitive or dynamic for the longitudinal monitoring of fibrosis 
progression/regression (Singh et al, 2015). LiverMultiScan™ (Perspectum 
Diagnostics, Oxford, UK) uses non-contrast multiparametric MRI to quantify hepatic 
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 fibro-inflammatory injury (iron-corrected T1 mapping), steatosis (PDFF) and iron 
content (T2* mapping). In patients, LiverMultiScan™ can accurately quantify liver 
disease (Banerjee et al., 2014; Wilman et al., 2017; Pavlides et al., 2017), may 
predict clinical outcomes (Pavlides et al, 2016),  and is now being adopted into 
clinical trial protocols as a surrogate endpoint. We hypothesized that multiparametric 
MRI could be developed and applied in experimental models of NASH and liver 
fibrosis using a small animal MR scanner system, with potential future utility in 
preclinical drug development studies whilst also addressing the principles of the 3Rs 
for humane animal research.  
 
RESULTS 
Assessment of hepatic fibro-inflammatory injury in rat CCl4 model 
To evaluate multiparametric MRI for the assessment of hepatic fibro-inflammatory 
injury in a preclinical setting we used the rat CCl4 model. Compared to OO controls, 
animals receiving CCl4 had higher serum transaminase levels and mild to moderate 
liver inflammation after both 4 and 12 weeks CCl4 (Fig. S1). Hepatic fibrogenic 
activity increased progressively, with 12-fold greater -SMA expression after 12 
weeks in CCl4-treated rats compared to controls (P=0.006) (Fig. S1). Hepatic 
collagen content (assessed by CPA) was increased, greater than 3-fold, after both 4 
weeks (P=0.043) and 12 weeks (P=0.013) CCl4 treatment relative to control (Fig. 
1A). 
After 4 weeks, liver T1 was 1025±112 ms in CCl4 rats compared to 984±138 ms in 
OO controls (d=40.68, 95% CI (-141.7, 223.1), P=0.621) (Fig. 1B,C). There was a 
significant difference in mean liver T1 in 12 week CCl4 rats (1122±78 ms) compared 
to controls (959±114 ms; d=162.7, 95% CI (11.92, 313.4), P=0.038) (Fig. 1B,C). 
There was a strong positive correlation between liver T1 values and collagen 
content after 12 weeks CCl4 (advanced fibrosis) (rs=0.717, P=0.037) (Fig. 1D) but 
this correlation was absent after 4 weeks of CCl4 (rs=-0.079, P=0.838) (early bridging 
fibrosis). 
To explore the influence of fat on hepatic T1, we used 1H-MRS to re-analyse two 
distinct areas identified by different signal intensity on the T2-weighted structural 
scan. Although one area had a much higher fat content, the T1 values were similar 
(Fig. S2).   
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Assessment of hepatic steatosis and steatotic inflammatory injury in 
preclinical liver injury models 
To explore the potential utility of multiparametric MRI as a non-invasive preclinical 
diagnostic method for the assessment and staging of NAFLD and evaluation of anti-
NASH treatments, we used the rat MCD diet model. Rats fed a MCD diet developed 
florid micro- and macro-vesicular steatosis (Fig. S3). The proportionate area of Oil 
Red O-stained fat in the liver was <0.5% in control rats, but in comparison was 
grossly elevated after 4 weeks MCD diet (22.9±10.9%; P=0.004) and 8 weeks MCD 
diet (30.2±13.2%; P=0.002) (Fig. 2B) with no significant difference between both 
timepoints.  
Quantification of hepatic fat by MRI (mean of 3 ROIs) showed a highly significant 
increase in PDFF after both 4 and 8 weeks of MCD diet, reaching 23.81±6.00% and 
23.84±5.64% compared with control animals where PDFF was 1.73±0.94% 
(P=0.0005) and 2.09±1.16% (P<0.0001), respectively (Fig. 2A,C). The hepatic PDFF 
strongly correlated with fat proportionate area (rs=0.819, P<0.0001) (Fig. 2F). 
Furthermore, hepatic PDFF correlated with both histological stage of steatosis and 
steatotic inflammatory injury (rs=0.850, P<0.0001 and rs=0.818, P<0.0001 
respectively) (Fig. 2D,E).  
In contrast to animals receiving MCD diet, CCl4 treated rats displayed a smaller 
increase in histological liver fat compared with controls after 4 weeks (8.94±6.48% 
vs. 0.26±0.19%, P=0.03) and 12 weeks (9.11±9.6% vs 0.30±0.13%, P=0.11) (Fig. 
3B). Quantification of hepatic fat by MRI (Fig. 3A) showed an increase in PDFF 
compared to controls after 4 weeks CCl4 (3.86±1.83% vs 0.91±0.93%, P=0.016) and 
12 weeks CCl4 (3.58±0.33% vs. 1.85±0.87%, P=0.0044) (Fig. 3C). Moreover, PDFF 
was strongly correlated with histological grading of steatosis (Oil Red O staining) 
and steatotic inflammatory injury (rs=0.74, P=0.003 and rs=0.84, P<0.0001 
respectively) (Fig. 3D,E). 
It had previously been shown that administration of cilostazol for 16 weeks reduced 
hepatic steatosis, inflammation and fibrosis in rats fed a choline-deficient, l-amino 
acid-defined (CDAA) diet or a high-fat high-calorie diet (Fujita et al., 2008). We 
tested our MRI methodology in rats that were fed MCD diet for 4 weeks plus 
treatment with cilostazol or vehicle control between weeks 2-4. Animals underwent 
multiparametric MRI at baseline and after 4 weeks. On histological examination, 
B
io
lo
gy
 O
pe
n 
• 
A
cc
ep
te
d 
m
an
us
cr
ip
t
 by guest on July 20, 2018http://bio.biologists.org/Downloaded from 
 cilostazol treatment for 2 weeks only reduced hepatic steatosis by approximately 5% 
(d=-5.19%, 95% CI (-13.91, 3.53), P=0.21), with a non-significant reduction in 
N(m)AS score (Fig. 4 A,B). Nevertheless, in a drug intervention setting 
multiparametric MRI methods performed similarly (Fig. 4C,D) and, importantly, 
strong correlations were observed between the histological assessment of steatotic 
inflammatory injury and MRI measures (PDFF; rs=0.675, P=0.019) (Fig. 4E). 
Assessment of hepatic iron content in preclinical liver injury models  
Hepatic iron may have a pathogenic role in NAFLD and, intriguingly, NAFLD itself 
may affect iron metabolism (Britton et al., 2016). From a technical standpoint, both 
hepatic steatosis and fibrosis can have confounding effects on T2* relaxation times. 
We showed histologically that CCl4 and MCD diet induced injury models were not 
associated with significant accumulation of iron in the liver (Figs S1, S3), but we did 
observe variable effects on T2* in these models (Fig. 5A). Consistent with the lack of 
tissue iron staining, there was no change in liver R2* (1/T2*) in CCl4 treated rats 
compared with controls (P>0.05) (Fig. 5B). However, we observed a significant 
increase in R2* (1/ T2*) in MCD diet-treated rat livers compared with controls at 4 
weeks (177.9±46.7s-1 vs. 76.2±7.9s-1, P<0.0001) and 8 weeks (213.6±22.5s-1 vs. 
83.6±12.1s-1, P<0.0001) (Fig. 5C). Moreover, there was a strong positive 
association between R2* and PDFF (rs=0.790, P<0.001) (Fig. 5D), indicating that 
steatosis had a cofounding effect on T2* relaxation time in this model.  
 
DISCUSSION 
Despite the identification of a large number of therapeutic targets from preclinical 
studies, there are currently no licensed drug treatments for liver fibrosis or for 
NASH. Drug development has been hindered by a reliance on liver biopsy and a 
lack of robust validated non-invasive biomarkers to diagnose and monitor changes 
in liver disease over time or in response to treatment. Multiparametric MRI using 
LiverMultiScan™ has shown promise as a clinical diagnostic tool and surrogate 
endpoint in therapeutic trials, especially in the assessment of NAFLD. Our objective 
was to develop and apply this non-invasive, contrast-free multiparametric MRI 
methodology in preclinical liver injury models that are commonly used in mechanistic 
and drug evaluation studies. 
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Here we showed that our multiparametric liver MRI protocol was feasible at 7.0 
Tesla in experimental rats and scanning was completed within a realistic time frame 
(~40 minutes, compared to ~85 minutes for a combined preclinical MRE and 
collagen molecular imaging protocol) (Zhu et al., 2017). Both hepatic T1 and PDFF 
changed with increasing duration of liver injury and were strongly correlated with 
histological assessments of fibrosis and steatosis/steatotic inflammatory injury, 
respectively. Unfortunately, there was only a minimal effect of a short treatment 
course of cilostazol in the MCD diet model and even histological endpoints were not 
significantly altered within this abbreviated timeframe. Although a number of MRI 
techniques have been evaluated individually in animal models to assess hepatic 
fibrosis (Zhu et al., 2017), iron content (Britton et al., 2016) or fat (Runge et al., 
2014), multiparametric MRI captures all of these parameters in a single contrast-free 
scan protocol. In a previous study in mice with fatty liver, non-invasive MR 
assessments (1H-MRS, PDFF and modified Dixon) had a higher correlation with 
liver triglyceride content than digital image analysis of Oil Red O stained liver 
sections (Runge et al., 2014). The authors concluded that MRI was the preferred 
method for fat quantification. The performance of LiverMultiScan™ in our 
experimental rat models was broadly similar to that observed in patients with CLD 
(rs=0.68, P<0.0001 for fibrosis; rs=0.89, P<0.001 for steatosis; rs=-0.69, P<0.0001 
for siderosis) (Banerjee et al., 2014).  
Our findings indicate that multiparametric liver MRI could potentially refine the way 
we currently approach testing of therapeutic candidates in preclinical models. Firstly, 
multiparametric MRI could be used as a quantitative and objective method to stratify 
liver disease severity before exposing animals to a drug treatment. It is known that 
animals maintained on an experimental lipogenic diet develop NAFLD at differing 
rates and of varying severity and, similarly to human disease, fibrosis accumulates 
heterogeneously within the liver. A pretreatment liver (wedge) biopsy protocol was 
previously used to categorize NAFLD mice into three groups (steatosis without 
fibrosis, NASH with fibrosis, cirrhosis), in order to address the inherent and 
potentially confounding issue of variability in the study population (Clapper et al., 
2013). Imaging with MRI could be used in a similar manner, especially where 
accurate stratification could permit a more precise evaluation of therapies that 
modulate different components of NAFLD pathogenesis (i.e. anti-steatotic, anti-
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 inflammatory, antifibrotic), but would have the advantages of being non-invasive and 
sampling the whole liver. Secondly, multiparametric MRI could potentially be used 
longitudinally to evaluate the effect of an antifibrotic or anti-NASH intervention in 
individual experimental animals, allowing each to serve as its own control, and 
thereby allowing determination of the distribution of effects in an experimental 
population (Clapper et al., 2013). This approach would also address the 3Rs 
(refinement, reduction, replacement) of humane animal experimentation.  
We acknowledge the limitations of this study. Firstly, this was an initial small 
feasibility study to determine whether a multiparametric MRI protocol could be 
successfully scaled down and applied in rats with chronic liver injury within a realistic 
timeframe. Our findings require further validation and confirmation of reproducibility, 
in order to use this test in longitudinal/interventional studies. Secondly, technical 
refinements to the protocol may increase robustness and reliability. The small organ 
size of rodents necessitates the use of high-field MR imaging systems to obtain 
adequate temporal and spatial resolution and poses major challenges to imaging 
due to shortened relaxation times and accentuated field inhomogeneity. Additionally, 
hepatic T1 values could potentially be influenced by the fat fraction, thus 
confounding its use as a quantitative marker of hepatic fibro-inflammatory injury. To 
explore this, we re-analyzed one rat using 1H-MRS that clearly had two distinct 
areas in the liver, one with a much higher fat content. However, the T1 value for 
both areas was the same. Nevertheless, in contrast to histological collagen 
quantification, we found that T1 mapping was not sufficiently sensitive to 
discriminate between normal liver and mild fibrosis (after 4 weeks CCl4). This 
remains the Achilles’ heel of non-invasive serum and imaging biomarkers in the 
clinical setting. Interestingly, a recent study in rats with liver fibrosis showed that 
MRE was only sensitive for the detection of late-stage fibrosis, whereas a collagen-
specific molecular imaging probe could only distinguish between earlier stages of 
fibrosis (Zhu et al., 2017). The differing sensitivity of various MRI methods indicates 
complementary staging capabilities and the potential for developing clinically-
relevant multiparametric composite MRI models. The utility of T2* as a quantifiable 
marker for iron overload is well established (Tanner et al., 2006) and T2* is currently 
the clinical standard for the non-invasive assessment of iron overload (Hernando et 
al., 2014). However, low tissue iron content in our rat liver injury models meant that 
we were unable to confirm the expected inverse relationship between increasing 
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 iron load and decreased T2 and T2* relaxation time in liver tissue. Furthermore, as 
demonstrated in this study, T2* is influenced by a number of factors independent of 
tissue iron concentration. In particular, we observed a significant shortening of T2* in 
the lipogenic MCD diet model, despite very low hepatic iron levels. This finding is 
consistent with previous human studies that confirm a short apparent T2* of fat 
(Bydder et al., 2008; O'Regan et al., 2008). 
Using multiparametric MRI to quantify liver injury in experimental animal models 
could be a powerful new tool to assist in the development of new therapies for CLD, 
and is directly translatable to clinical practice. 
 
MATERIALS AND METHODS 
Animal models 
Animal experiments (Fig. 6) were conducted with local and Government ethical 
approval and in compliance with the Use of Animals in Scientific Procedures Act 
1986. Experiments were designed and implemented according to NC3R ARRIVE 
guidelines. We calculated group sizes prospectively for the animal model 
experiments based upon our previously published data using the carbon 
tetrachloride (CCl4) model (Fallowfield et al., 2014). A sample size of ≥5 rats per 
group was computed using G*Power version 3.1.2 given α = 0.05, power (1 − β) = 
0.9, and effect size (d) = 2.64. Cage-mates were randomized to treatment or control 
groups, and all surviving rats at designated endpoints were included in the data 
analysis. No animals or potential outliers were excluded from the datasets 
presented. Biochemical and histological assessments were performed in a blinded 
manner. Animals were housed under standard conditions (12:12h light-dark cycle, 
temperature 23±2°C, with free access to chow and water), 3 rats per cage, and were 
acclimatized to the room for 1 week before the beginning of the experiments.  
Rat carbon tetrachloride (CCl4) model 
Chronic carbon tetrachloride (CCl4) intoxication in rodents is a reproducible, well-
characterized model that induces liver fibrosis (after ~4 weeks) and cirrhosis (after 
~12 weeks). Liver injury was induced in 8-week old (250-300g) male wild-type 
Sprague-Dawley rats by twice-weekly intraperitoneal (i.p.) injection of 0.2 mL/100g 
CCl4 (Sigma-Aldrich, Gillingham, UK) in a 1:1 ratio with sterile olive oil vehicle (OO; 
Sigma-Aldrich, Gillingham, UK), for either 4 or 12 weeks (n=6 per group). Littermate 
control rats (n=4 per group) were injected with an identical volume of OO. Animals 
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 underwent MRI at the end of the 4- or 12-week treatment course under inhalational 
general anesthesia (1–2% isoflurane in oxygen) without recovery. Body weight, liver 
and spleen weights were recorded and liver tissue and blood were collected for 
histological and biochemical analysis. One of the 12-week CCl4-treated animals was 
euthanized prematurely due to poor health and excluded from analysis.  
Methionine and choline deficient diet model 
The methionine and choline deficient (MCD) diet is a frequently used rodent model of 
NASH. After 4 weeks of MCD diet, aminotransferase levels are elevated and hepatic 
histology shows florid centrilobular hepatocellular steatosis, whilst 8 weeks of MCD 
diet results in NASH and early fibrosis. Steatohepatitis was induced in 8-week old 
(250-300g) male wild-type Sprague-Dawley rats by feeding a lipogenic MCD diet 
(Research Diets, New Jersey, USA) for 4 or 8 weeks (n=6 per group). Littermate 
control rats received standard chow (n=4 per group). Animals underwent MRI at the 
end of the 4- or 8-week treatment course under inhalational general anesthesia (1–
2% isoflurane in oxygen) without recovery. Body weight, liver and spleen weights 
were recorded and liver tissue and blood were collected for histological and 
biochemical analysis.  
In a separate experiment, rats were fed an MCD diet for a total of 4 weeks. After 2 
weeks, animals were randomized to treatment with either 100 mg/kg/day of cilostazol 
(a phosphodiesterase type-3 inhibitor previously shown to reduce steatohepatitis in 
experimental NAFLD models (Fujita et al., 2008)) or vehicle by daily gavage from 
week 2 to week 4 (n=6 per group). Animals underwent MRI at baseline and after 4 
weeks.  
In vivo MR imaging 
All animals were continually monitored for vital signs and to maintain depth of 
anesthesia. Respiration rate was monitored by detection of breathing motion by 
compression of a respiratory sensor placed in contact with the abdomen and core 
temperature by a rectal thermometer. 
Multiparametric liver MRI 
Imaging studies were performed in anesthetized rats using a 7.0 Tesla preclinical 
MRI scanner (Agilent Technologies, Santa Clara, CA, USA), with a 72 mm internal 
diameter volume coil. At each timepoint, the following scans were run: two gradient-
echo scans with arrayed echo times (repetition time (TR) 75 ms, 4 averages, flip 
angle 20º), one scan with 4 in-phase echoes (1.01, 2.02, 3.03, 4.04 ms) and one 
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 with 4 out-of-phase echoes (1.52, 2.53, 3.54, 4.55 ms), to measure fat using a 3-
point Dixon method, and T2* using the 4 in-phase echoes. An adapted gradient echo 
(fast low angle shot (FLASH)) Look-Locker sequence was used to measure T1 
(acquired with 5 inversion times ranging from 270 to 5100 ms), 2 averages, flip angle 
8º, echo train length 32). All scans were respiratory gated with a field of view (FOV) 
60 mm × 60 mm, 2 mm thick single slice, 128 x 128 matrix. The pulse sequence was 
based on previous work (Li et al., 2010), but was adapted to use an inversion 
recovery module rather than a saturation module. The axial slice was positioned to 
cover an abdominal region containing primarily liver. Depending on respiration and 
anesthesia levels, the full set of scans including shimming and localization were 
completed in 40-50 min. 
MR image analysis 
Data was exported in phase and magnitude format. T2* was determined using the in-
phase gradient echo data (Bonny et al., 1996). Pixels in which the magnitude failed 
to exceed the background noise by 2-fold (Bonny et al., 1996) were excluded from 
the analysis. A combination of the in-phase and out-of-phase gradient echo data 
were used to calculate proton density fat and water maps using the extended 3-point 
Dixon approach (Glover and Schneider, 1991). The PDFF was calculated from the 
fat (F) and water (W) maps as  
𝑃𝐷𝐹𝐹 =
𝐹
𝐹 +𝑊
 
T1 maps were calculated from the Look-Locker data as described previously 
(Deichmann et al., 1992). From each of the T1, T2* and PDFF maps three circular 
regions of interest (ROI) were collected per time point per animal. ROI placement 
was in the in left, right and central region of each liver in a location where there was 
no visible motion artefact or signal voids due to bowel gas. Vessels and non-liver 
regions were not included in ROIs.  
To investigate the potential effect of parenchymal fat on hepatic T1, we also 
performed localized proton magnetic resonance spectroscopy (1H-MRS) using a 
point resolved spectroscopy (PRESS) sequence at two distinct locations depicting 
different signal intensity on the T2-weighted structural scan. The voxel dimensions 
were 4 × 4 × 4 mm, TR = 3 s and echo time (TE) = 23 ms. One signal average was 
used. 
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 Serum liver enzyme measurement 
Serum alanine aminotransferase (ALT), was measured as described previously 
(Bergmeyer et al., 1978) utilizing a commercial kit (Alpha Laboratories Ltd., 
Eastleigh, UK). Aspartate aminotransferase (AST) was determined by a commercial 
kit (Randox Laboratories, Crumlin, UK). Total bilirubin was determined by the acid 
diazo method (Pearlmen et al., 1974) using a commercial kit (Alpha Laboratories 
Ltd., Eastleigh, UK). All assays were adapted for use on a Cobas Fara centrifugal 
analyzer (Roche Diagnostics Ltd., Welwyn Garden City, UK). Within-run precision of 
these assays was calculated and expressed as coefficient of variation (CV) < 4%, 
while intra-batch precision was CV < 5%. 
Liver histology assessments 
Liver tissue was fixed in 4% phosphate-buffered formaldehyde and embedded in 
paraffin, or in OCT and frozen on dry ice and stored at −80°C until histological 
analysis. Five-micron sections were stained for activated hepatic stellate cells by 
alpha-smooth muscle actin (-SMA) (A2547; Sigma-Aldrich, Gillingham, UK) and 
interstitial fibrosis by picrosirus red, as described previously (Fallowfield et al., 
2014). Histology was assessed independently by an expert liver histopathologist, 
blinded to treatment allocation. Livers were staged for fibrosis by the injury-
independent modified Ishak score (scale 0-6; Table S1). Both CCl4 and MCD diet 
induce steatosis and lobular necroinflammation, modeling histological features 
characterizing NAFLD. In human disease, this is assessed by application of the 
NAFLD activity score (NAS). The same features of steatotic inflammatory injury in 
the rodent models were scored on a scale from 0 to 8 (steatosis 0-3, lobular 
inflammation 0-3 and hepatocyte ballooning 0-2) on hematoxylin and eosin (H&E) 
stained sections using the same criteria (and referred to as the NAFLD (model) 
Activity Score (N(m)AS) to reflect this application (Kleiner et al., 2005). Hepatic iron 
(ferric form) was detected using Perls’ Prussian Blue and scored using the Scheuer 
method (Scheuer et al.,1962) with grade 0 being negative and grades 1, 2, 3, and 4 
representing increasing amounts of stainable iron. Frozen sections were stained 
with Oil Red O to assess liver fat content. Sections were analyzed using an 
AxioScan Z1 slide scanner at x20 magnification and ImageJ software (NIH, 
Bethesda, USA) to quantify the collagen proportionate area (CPA), -SMA and Oil 
Red O staining, assessed by a blinded assessor.   
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Statistical analysis 
Statistical analysis was performed using GraphPad Prism Version 6.0 (GraphPad 
Software Inc., San Diego, USA). One-way analysis of variance (ANOVA) with 
Tukey’s post-hoc test was used to assess differences between groups. Spearman’s 
rank-order correlation (rs) was used to examine associations. For all tests, a P-value 
<0.05 was taken to indicate statistical significance. Graphical data is presented as 
mean±standard deviation (SD).  
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Figures 
 
 
 
Fig. 1. MRI assessment of hepatic fibro-inflammatory injury in rat CCl4 model. 
A) Quantification of hepatic collagen content (% area of picrosirius red staining). B) 
Representative examples of transverse liver MR T1 relaxation maps. C) T1 
relaxation quantification in rats receiving CCl4 or olive oil (OO) for 4 and 12 weeks. 
D) Correlation between hepatic collagen content and T1 in rats receiving CCl4 and 
OO for 12 weeks. Data presented as mean±SD, analyzed by unpaired t-test 
(*P<0.05, **P<0.01). Spearman (rs) correlation coefficient was used to examine 
correlations.  
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Fig. 2. MRI assessment of hepatic steatosis and steatotic inflammatory injury 
in rat MCD diet model. A) Representative examples of transverse liver MR PDFF 
maps. B) Quantification of Oil red O (ORO) staining of hepatic fat. C) Quantification 
of hepatic proton density fat fraction (PDFF). Correlations between hepatic PDFF 
and D) histologically assessed steatosis, E) steatotic inflammatory injury (N(m)AS) 
score and F) ORO staining in rats receiving MCD or control diet (N) for 4 and 8 
weeks. Data presented as mean±SD, analyzed by unpaired t-test (**P<0.01, 
***P<0.001, ****P<0.0001). Spearman (rs) correlation coefficient was used to 
examine correlations.  
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Fig. 3. MRI assessment of hepatic steatosis and steatohepatitis in rat CCl4 
model. A) Representative examples of transverse liver MR PDFF maps. B) 
Quantification of Oil red O (ORO) staining of hepatic fat. C) Quantification of hepatic 
proton density fat fraction (PDFF). Correlations between hepatic PDFF and D) 
histologically assessed ORO staining and E) steatotic inflammatory injury (N(mAS) 
score in rats receiving CCl4 or olive oil (OO) for 4 and 12 weeks. Data presented as 
mean±SD, analyzed by unpaired t-test (*P<0.05, **P<0.01). Spearman (rs) 
correlation coefficient was used to examine correlations.  
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Fig. 4. MRI assessment of hepatic steatosis and steatohepatitis in cilostazol 
treated rats on MCD diet. Sprague-Dawley rats received MCD diet for 4 weeks 
plus cliostazol or vehicle for the last 2 weeks of the model. Animals were scanned at 
baseline and after 4 weeks. A) Quantification of hepatic fat by morphometry based 
on H&E staining. B) Steatotic inflammatory injury (N(m)AS) score. C) 
Representative examples of transverse liver MR proton density fat fraction (PDFF). 
D) Quantification of hepatic PDFF. E) Correlation between PDFF and steatotic 
inflammatory injury (N(m)AS) score. Data presented as mean±SD, analyzed by 
unpaired t-test. Spearman (rs) correlation coefficient was used to examine 
correlations.  
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Fig. 5. MRI assessment of T2*/R2* relaxation in preclinical liver injury models. 
A) Representative examples of transverse liver MR T2* maps. B) Quantification of 
R2* (1/T2*) in rats receiving CCl4 or olive oil (OO) for 4 and 12 weeks. C) 
Quantification of R2* (1/T2*) in rats receiving MCD or control diet (N) for 4 and 8 
weeks. D) Correlation between R2* and PDFF in animals receiving CCl4 or OO 
injections and MCD or control diets. Data presented as mean±SD, analyzed by 
unpaired t-test (****P<0.0001). Spearman (rs) correlation coefficient was used to 
examine correlations.  
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Fig. 6. Rat models of chronic liver disease.  
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Supporting Information 
 
Fig. S1. Characterization of rat CCl4 model. Liver histology and serum markers were 
assessed in male Sprague-Dawley rats receiving CCl4 or olive oil (OO) injections for 4 or 
12 weeks. A) Representative liver staining images of: alpha-smooth muscle actin (-
SMA) staining of activated hepatic stellate cells, pircosirius red (PSR) staining of fibrillar 
collagen, hematoxylin and eosin (H&E), Perls’ Prussian Blue (PPB) staining of iron, Oil 
Biology Open (2018): doi:10.1242/bio.033910: Supplementary information
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Red O (ORO) fat staining. B) Serum alanine aminotransferase (ALT) levels. C) Serum 
aspartate aminotransferase (AST) levels. D) Iron score based on PPB staining. Data 
presented as mean±SD, analyzed by unpaired t-test (*P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001).  
 
Fig. S2. Influence of fat on hepatic T1. A) Transverse liver MR T1 relaxation map. B) 
Transverse liver MR proton density fat fraction (PDFF) map. C) Structural T2-weighted 
MRI scan with marked voxels. D) Magnetic resonance spectroscopy (MRS) spectra 
acquired from voxel 1, and E) MRS spectra acquired from voxel 2.  Peak assignment is 
as follows, 1: H2O, 2: Olefinic protons (CH=CH-), 3: Methylene protons (-CH=CHCH2-), 
4: Methylene protons (-CH2-), 5: Methyl protons (-CH3). 
Biology Open (2018): doi:10.1242/bio.033910: Supplementary information
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 Fig. S3. Characterization of MCD diet model. Liver histology and serum markers were 
assessed in male Sprague-Dawley rats receiving MCD or control diet (N) for 4 or 8 weeks. 
A) Representative liver staining images of: alpha-smooth muscle actin (-SMA) staining 
of activated hepatic stellate cells; picrosirius red (PSR) staining of fibrillar collagen; 
hematoxylin and eosin (H&E), Perls’ Prussian Blue (PPB) staining of iron; Oil Red O 
(ORO) fat staining. B) Serum aspartate aminotransferase (AST) levels. C) Serum alanine 
aminotransferase (ALT) levels. D) Inflammation score based on H&E staining. E) 
Modified Ishak fibrosis score. F) Quantification of -SMA staining by morphometry. G) 
Iron score based on PPB staining. Data presented as mean±SD, analyzed by unpaired 
t-test (**P<0.01).   
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Score Description 
Fibrosis 
Severity 
0 No fibrosis None 
1 
Zonal fibrosis involving a minority of portal tracts and/or 
zone 3 areas 
Mild 
2 
Zonal fibrosis involving a majority of portal tracts and/or 
zone 3 areas 
Mild 
3 Bridging fibrosis - occasional foci Moderate 
4 Bridging fibrosis – widespread Moderate 
5 
Bridging fibrosis – widespread, with occasional nodules 
(incomplete/early cirrhosis) 
Severe 
6 Cirrhosis, probable or definite Severe 
 
Table S1. Modified Ishak score for hepatic fibrosis 
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